Protocol Page


	Study ID (Protocol Number)
	IM101-226


	STUDY LOCATIONS*
	Alan J. Kivitz, Md, Cpi Duncansville, PA 16635 Completed	Clinical Pharmacology Study Group Worcester, MA 01605 Active, not recruiting
	Carolina Arthritis Associates Wilmington, NC 28401 Active, not recruiting	Coeur D'Alene Arthrit Clin Coeur D Alene, ID 83814 Active, not recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
	STUDY OVERVIEW
	The primary purpose of the protocol is to show that Abatacept can induce remission after 12 months of treatment and then maintained remission following 6 months of drug withdrawal.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.